Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
UAE approves gene therapy for spinal muscular atrophy in children age 2 and up.
The UAE has approved Itvisma (onasemnogene abeparvovec), a gene therapy for spinal muscular atrophy (SMA), for patients aged two and older, becoming the second country globally to do so.
The Emirates Drug Establishment (EDE) granted approval based on clinical evidence showing sustained motor function improvements and a favorable safety profile.
The treatment uses an adeno-associated viral vector to replace the defective gene causing SMA.
EDE officials highlighted the UAE’s efficient, science-driven regulatory process, balancing speed, rigor, and transparency.
The move supports the UAE’s vision for a sustainable, knowledge-driven healthcare system and strengthens its role as a regional hub for medical innovation.
Novartis, the manufacturer, praised the approval as a step toward equitable access to breakthrough therapies for rare genetic diseases.
Emiratos Árabes Unidos aprueba la terapia genética para la atrofia muscular espinal en niños de 2 años o más.